

Motuporin, A Potent Protein Phosphatase Inhibitor Isolated from the Papua New Guinea Sponge *Theonella swinhoei* Gray

E. Dilip de Silva, David E. Williams and Raymond J. Andersen*

Departments of Chemistry and Oceanography
University of British Columbia
Vancouver, B.C., CANADA V6T 1Z4

Heide Klix and Charles F.B. Holmes*

MRC Group in Protein Structure and Function
Department of Biochemistry
University of Alberta
Edmonton, Alberta, CANADA T6G 2H7

Theresa M. Allen*

Department of Pharmacology
University of Alberta
Edmonton, Alberta, CANADA T6G 2H7


Abstract: Motuporin (1), a cyclic pentapeptide that is a potent protein phosphatase-1 inhibitor and cytotoxin, has been isolated from the marine sponge *Theonella swinhoei* collected in Papua New Guinea. The structure of motuporin was elucidated by spectroscopic analysis and chemical degradation.

Marine sponges belonging to the genus *Theonella* are proving to be a rich source of biologically active cyclic peptides that usually contain at least one previously unknown amino acid. The *Theonella* peptides reported to date include; orbiculamide A,¹ keramamides B to D,² cyclothoenamides A and B,³ theonellamide F,⁴ the theonellopeptolides,⁵ and theonellamine B.⁶ As part of an ongoing investigation of bioactive metabolites isolated from marine invertebrates collected in Papua New Guinea,⁷ it was found that crude extracts of the sponge *Theonella swinhoei* Gray⁸ inhibited protein phosphatase-1 even at extremely high dilution. Enzyme assay-guided fractionation^{9a} of the crude extracts led to the isolation of motuporin (1), a novel cyclic pentapeptide. Motuporin (1) inhibits protein phosphatase-1 in a standard phosphorylase phosphatase assay at a concentration of <1 nmolar, making it one of the most potent PP1 inhibitors known,⁹ and it also displays considerable *in vitro* cytotoxicity against murine leukemia (P388: IC₅₀ 6µg/mL), human lung (A549: IC₅₀ 2.4µg/mL), ovarian (HEY: IC₅₀ 2.8µg/mL), colon (LoVo: IC₅₀ 2.3µg/mL), breast (MCF7: IC₅₀ 12.4µg/mL) and brain (U373MG: IC₅₀ 2.4µg/mL) cancer cell lines.

Specimens of *T. swinhoei* were collected by hand using SCUBA on nearshore reefs off Motupore Island, Papua New Guinea. Freshly collected sponge was frozen on site and transported to Vancouver over dry ice. Thawed sponge (≈250g dry wt.) was extracted repeatedly with methanol (3 x 500mL) and the combined extracts were concentrated *in vacuo* before being partitioned between hexanes and water. The PP1 inhibitory aqueous phase was next partitioned between CHCl₃ and methanol/water (4:7) to give an inhibitory aqueous

phase that was chromatographed on Sephadex LH20 (eluent: methanol) and preparative reversed phase TLC (Whatman RP KC₁₈F: methanol/H₂O 6:4) to give pure motuporin (**1**) as an optically active ($[\alpha]_D -83.8^\circ$) clear glass (≈ 54 mg).¹⁰

Motuporin (**1**) showed parent ions at m/z 812 (± 2) (C₄₀H₅₅N₅O₁₀Na₂) and 790 (± 2) (C₄₀H₅₆N₅O₁₀Na) Da in the LRFABMS. Doping the matrix with potassium chloride shifted the FABMS peaks to m/z 845 (± 2) (C₄₀H₅₅N₅O₁₀K₂) and 806 (± 2) (C₄₀H₅₆N₅O₁₀K) in agreement with the presence of one or two metal atoms in the parent ions. Dimethylmotuporin (**2**), prepared by treating motuporin (**1**) with MeI/K₂CO₃ in DMF at rt overnight, gave a parent ion in the EIHRMS at m/z 795.4421 appropriate for a molecular formula of C₄₂H₆₁N₅O₁₀ ($\Delta M +0.3$ mmu). The peptidic nature of motuporin was indicated by its ¹H and ¹³C nmr data (Table 1). COSY, HMQC, HMBC and nOe-difference experiments readily identified valine, glutamic acid, β -methylaspartic acid and N-methyl-(Z)-dehydrobutyryne residues in **1** (Table 1).



The remaining portion of motuporin (C₂₀H₂₇NO₂) was shown by analysis of both ¹³C and ¹H nmr data for **1** and its dimethyl ester **2** (Table 1) to belong to the β -amino acid Adda, that had previously been reported from the blue-green algal toxins microcystin-LR and nodularin.¹¹ The chemical shifts, coupling patterns and nOe behaviour of the resonances assigned to the Adda residue in motuporin (**1**) were essentially identical to those previously reported for the microcystins¹² and nodularin¹¹ in agreement with identical constitutions and relative stereochemistries for all known Adda residues. Motuporin's molecular formula (C₄₀H₅₇N₅O₁₀) required fifteen sites of unsaturation. Fourteen of these could be accounted for by functionality in the identified amino acid residues and the final site was attributed to a macrocyclic pentapeptide ring.

HMBC and nOe data collected on the dimethyl ester **2** provided information on the amino acid sequence in motuporin. Correlations between the methyl ester protons (δ 3.73 and 3.88) and the C1 carboxyl carbons (δ 172.6 and 172.7; Table 1) of the glutamic acid and β -methylaspartic acid residues established the γ -Glu and β -MeAsp peptide linkages. Irradiation of the Glu NH resonance (39NH: δ 6.66) induced nOes in H2 (δ 2.76) and H39 (δ 4.37) demonstrating a peptide link between the Adda carboxyl and the Glu amino group. HMBC correlations from the N-methyl protons (Me35: δ 3.09) of the NMe Δ But residue and a γ -methylene proton (H37': δ 2.39) of the Glu residue to the δ -carboxyl group (C36: δ 172.2) of the Glu residue connected Glu to NMe Δ But. HMBC correlations from the NMe Δ But olefinic proton (H33: δ 7.02) and the β -methylaspartic acid NH proton (28NH: δ 8.13) to the NMe Δ But carboxyl carbon (C31: δ 164.2) linked NMe Δ But to β -MeAsp and a

Table1	Motuporin (1) (MeOH-d ₄)				Dimethylmotuporin (2) (CDCl ₃)			
Carbon#	¹ H 500MHz ^a	nOe ^b	¹³ C ^c	HMBC ^d	¹ H 500MHz ^a	nOe ^b	¹³ C ^c	HMBC ^d
ADDA								
1			176.4	H:17			174.9	39NH
2	3.02,dd(10.5,7)		44.8	H:17	2.76,m		43.8	
3	4.61,dd(10.5,9)		56.0	H:2,5,17	3.87-3.90		59.1	H:5,17
4	5.61,dd(15.5,9)		127.3		5.86,dd(15.5,9)		124.1	
5	6.22,d(15.5)		138.4	H:18	6.11,d(15.5)		138.4	H:7
6			134.2	H:8,18			132.6	H:4,18
7	5.39,d(9.5)		136.4	H:8,18,19	5.32,d(10)		135.9	H:5,8,18,19
8	2.57,m		37.7	H:19	2.55,m		36.7	
9	3.21-3.25		88.5	H:8,10,10',19,20	3.17,m		86.9	H:10,19,20
10	2.65,dd(14,7)		39.0	H:8,12,16	2.66,dd(14,7.5)		38.3	H:12,16
10'	2.81,dd(14,4.5)				2.76,m			
11			140.6	H:10,10',13,15			139.3	H:10,10',13,15
12	7.13-7.20,m		130.5	H:10,10',14	7.16,m		129.4	H:10,10',14,16
13	7.23,m		129.2	H:12,15	7.23,m		128.2	H:15
14	7.13-7.20,m		127.0	H:12,16	7.16,m		126.0	H:12,16
15	7.23,m		129.2	H:13,16	7.23,m		128.2	H:13
16	7.13-7.20,m		130.5	H:10,10',14	7.16,m		129.4	H:10,10',14,12
17	1.02,d(7)		16.4 ^e		0.99,d(6.5)		14.9	
18	1.62,s	H4,H8	13.0				12.7	H:5,7
19	0.99,d(6.5)		16.5 ^e	H:8	0.99,d(6.5)		16.2	H:8
20	3.23,s		58.7		3.21,s		58.6	H:9
3NH					6.89,bd(6)	H22		
VAL								
21			171.8	H:22			170.2	H:22
22	4.40,bd(3.5)		57.7	H:24,25	4.22,dd(9.3,5.7)	H23	57.9	H:25
23	2.49,m		30.1	H:24,25	2.04,m		30.0	H:24,25
24	0.76,d(6.5) ^e		16.5 ^e	H:25	0.82,d(7) ^f		17.8 ^e	H:22,25
25	0.84,d(7) ^e		19.8	H:24	0.87,d(6.7) ^f	H23	19.4 ^e	H:24
22NH					6.06,bd(9.5)			
βMeASP								
26			177.9	H:28,30			173.9	H:28,30
27	3.21-3.25,m		40.8	H:30	2.86,m		40.4	H:28,30
28	4.20,bd(3)		60.4	H:30	4.40,bd(6.7)		56.2	H:30
29			177.1	H:28			172.7 ^f	H:28,41
30	1.20,d(7)	H28	16.6 ^e		1.30,d(6)	H28,28NH	15.8	
28NH					8.13,bd(6.7)	H35		
NMeABUT								
31			165.7	H:33			164.2	H:33,28NH
32			137.9	H:34,35			135.4	H:34
33	6.94,q(7.5)		136.6		7.02,q(7)	H34	136.4	H:34
34	1.74,d(7.5)		13.2	H:33	1.72,d(7)		13.2	H:33
35	3.07,s	H34	35.0		3.09,s		34.6	
GLU								
36			175.7	H:37,37'			172.2	H:35,37'
37	2.04,ddd(16.4,12.2,4.5)		29.7	H:38'	2.04,m		29.2	H:38',39
37'	2.73,ddd(16.4,12.8,4.0)				2.39,m			
38	1.81,m		28.8	H:37,37'	2.05,m		26.0	H:37,37',39
38'	2.27,m				2.55,m			
39	4.45,bt(4.3)		54.4		4.37,td(7.5,3)		52.9	
40			178.3				172.6 ^f	H:39,42,39NH
39NH					6.66,bd(7)	H2,H39		
OMe41					3.73,s ^g		52.5 ^g	
OMe42					3.88,s ^g		53.4 ^g	

^aAssignments based on double resonance, COSY60 and DQF-COSY. ^bProton in C# column irradiated. ^cAssignments based on HMQC and HMBC correlations. ^dProtons correlated to carbon resonances in ¹³C column. ^{e,f,g}Interchangeable.

nOe from the Adda NH (3NH: δ 6.89) to the Val α -proton (H22: 4.22) linked the Adda amino group to the Val carboxyl. The final peptide linkage required to complete the macrocycle had to be between the Val amino group and the γ -carboxyl of the β -MeAsp residue.

The configurations of the amino acids in motuporin (1) were determined by hydrolysis (6N HCl: reflux 12h) and derivatization with Marfey's reagent followed by HPLC analysis.¹³ D-Glutamic acid and L-valine were directly identified by this method and D-erythro- β -methyl aspartic acid was identified by comparing the derivatized hydrolysis products of motuporin (1) to the derivatized hydrolysis products of authentic microcystin-LR.¹⁴ As indicated above, nmr analysis showed that the Adda residue in 1 and in microcystin-LR had the same relative configurations. Ozonolysis of motuporin with oxidative workup (H_2O_2), followed by hydrolysis (6N HCl) and derivatization with Marfey's reagent, liberated a second equivalent of derivatized D-erythro- β -methyl aspartic acid from the Adda residue. A similar result was observed when authentic microcystin-LR was ozonized (H_2O_2 workup) and hydrolyzed (6N HCl). Therefore, the Adda residue in motuporin has the 2S,3S,8S,9S configuration found in microcystin-LR and nodularin and the complete structure of motuporin is as shown in 1.

Motuporin (1) is only the second cyclic pentapeptide in this class and it is the first example that has been isolated from a marine source. It differs from the fresh-water blue-green algal toxin nodularin^{11b} by the replacement of a polar arginine residue with a nonpolar valine residue. Motuporin is a potent PP1 inhibitor and cytotoxin which demonstrates that the arginine residue is not essential for biological activity in this class of peptides. Inhibitors are vital tools in the study of the role of protein phosphatases in cell biology. Motuporin should help contribute to our understanding of these enzymes, which regulate important hormone and growth factor intracellular signalling pathways.⁹ The structural similarity between motuporin and nodularin provides strong evidence that motuporin is being produced by a blue-green alga.

Acknowledgements: Financial support was provided by the Natural Sciences and Engineering Research Council of Canada (RIA), the National Cancer Institute of Canada (RJA and TMA), the Medical Research Council of Canada (CFBH) and the Alberta Heritage Foundation for Medical Research (CFBH). The authors wish to thank Professor R.W.M. van Soest⁸ for identifying the sponge, M. LeBlanc, M. Doweay and C. Arneson for assisting the collection and G. Kao for conducting the cytotoxicity bioassays.

References:

- [1] Fusetani, N.; Sugawara, T.; Hirota, H. *J. Amer. Chem. Soc.* **1991**, *113*, 7811.
- [2] Kobayashi, J.; Itagaki, F.; Shigemori, H.; Ishibashi, M.; Takahashi, K.; Oguru, M.; Nagasawa, S.; Nakamura, T.; Hirota, H.; Ohta, T.; Nozoe, S. *J. Amer. Chem. Soc.* **1991**, *113*, 7812.
- [3] Fusetani, N.; Matsunaga, S.; Matsumoto, H.; Takebayashi, Y. *J. Amer. Chem. Soc.* **1990**, *112*, 7053.
- [4] Matsunaga, S.; Fusetani, N.; Hashimoto, K.; Walchli, M. *J. Amer. Chem. Soc.* **1989**, *111*, 2582.
- [5] Kitigawa, I.; Kobayashi, M.; Lee, N.K.; Shibuya, H.; Kawata, Y.; Sakiyama, F. *Chem. Pharm. Bull.* **1986**, *34*, 2664.
- [6] Nakamura, H.; Kobayashi, J.; Nakamura, Y.; Ohizumi, Y.; Kondo, T.; Hirata, Y. *Tetrahedron. Lett.* **1986**, *27*, 4319.
- [7] for previous studies see: Burgoyne, D.L.; Andersen, R.J.; Allen, T.M. *J. Org. Chem.* in press, and b) de Silva, E.D.; Racok, J.S.; Andersen, R.J.; Allen, T.M.; Brinen, L.S.; Clardy, J. *Tetrahedron Lett.*, **1991**, *32*, 2707.
- [8] Identified by Dr. R. W.M. van Soest. A voucher sample is deposited at the Zoological Museum of Amsterdam (PNG 24/11/88, Motupore).
- [9] a) Holmes, C.F.B. *Toxicon* **1991**, *29*, 469, and b) Cohen, P.; Holmes, C.F.B.; Tsukitani, Y. *Trends Biochem. Sci.* **1990**, *15*, 98. Further studies on the phosphatase inhibition properties and cytotoxicity of motuporin are ongoing and the results will be reported elsewhere.
- [10] A minor constituent was also isolated. Its ¹H nmr spectrum indicated that it differed from motuporin (1) simply by the substitution of isoleucine for valine. The limited quantity of the minor metabolite prevented complete characterization.
- [11] a) Botes, P.B.; Wessels, P.L.; Kruger, H.; Runnegar, M.T.C.; Santikarn, S.; Smith, R.J.; Barna, J.C.J.; Williams, D.H. *J. Chem. Soc. Perkin Trans. I*, **1985**, 2747, and b) Rinehart, K.L.; Harada, K.; Namikoshi, M.; Chen, C.; Harvis, C.; Munro, M.H.G.; Blunt, J.; Mulligan, P.; Beasley, V.; Dahlem, A.; Carmichael, W. *J. Amer. Chem. Soc.* **1988**, *110*, 8557.
- [12] a) Botes, D.; Tuinman, A.; Wessels, P.; Viljoen, C.; Kruger, H.; Williams, D.H.; Santikarn, S.; Smith, R.; Hammond, S. *J. Chem. Soc. Perkin Trans. I*, **1984**, 2311, and b) Painuly, P.; Perez, R.; Fukai, T.; Shimizu, Y. *Tetrahedron Lett.* **1988**, *29*, 11.
- [13] Marfey, P. *Carlsberg Res. Commun.* **1984**, *49*, 591.
- [14] Obtained from Calbiochem.

(Received in USA 12 December 1991)